Please assess the completion status of the following clinical trial:

Trial Title: Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Active ulcerative proctitis~* Diagnosis confirmed by endoscopy~* Established disease or new diagnosis~Exclusion Criteria:~* Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, diverticular assoc. colitis, microscopic colitis~* Presence of proctitis of a different origin~* Prior bowel resection~* Presence of symptomatic organic disease of the gastrointestinal tract~* Asthma, tuberculosis, cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, infection if careful medical monitoring is not ensured~* Local intestinal infection~* Abnormal hepatic or renal function~* Oral/rectal/intravenous corticosteroids therapy~* Existing or intended pregnancy or breast-feeding~* Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide dosage 1 (Type: EXPERIMENTAL): Budesonide 2 mg suppository
- Budesonide dosage 2 (Type: EXPERIMENTAL): Budesonide 4 mg suppository
- Mesalazine (Type: ACTIVE_COMPARATOR): Mesalazine 1g suppository
- Combination (Type: EXPERIMENTAL): Budesonide 2 mg suppository/Mesalazine 1 g suppository

Based on this trial design, predict the completion outcome and termination type (if applicable).